| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
23,309 |
17,879 |
$3.96M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
10,393 |
6,637 |
$2.12M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
18,407 |
15,918 |
$2.09M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
9,301 |
7,041 |
$692K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,503 |
2,917 |
$606K |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,272 |
3,031 |
$572K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
3,327 |
2,504 |
$513K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
16,175 |
4,092 |
$494K |
| G0378 |
Hospital observation service, per hour |
4,147 |
1,672 |
$466K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
9,352 |
4,356 |
$435K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
11,292 |
8,464 |
$430K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
8,177 |
6,453 |
$414K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,808 |
1,595 |
$386K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,802 |
4,283 |
$385K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,649 |
8,107 |
$344K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
848 |
394 |
$309K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
7,735 |
6,418 |
$292K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
13,478 |
7,321 |
$283K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,741 |
3,404 |
$268K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
5,954 |
1,687 |
$239K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,292 |
2,831 |
$236K |
| 71045 |
Radiologic examination, chest; single view |
9,726 |
6,085 |
$225K |
| 80053 |
Comprehensive metabolic panel |
29,315 |
18,201 |
$221K |
| 71046 |
Radiologic examination, chest; 2 views |
6,160 |
5,018 |
$193K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
2,706 |
1,398 |
$172K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
25,695 |
19,333 |
$160K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,730 |
963 |
$118K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
11,155 |
8,450 |
$113K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,709 |
2,315 |
$113K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
3,318 |
1,788 |
$108K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,168 |
1,636 |
$107K |
| 84484 |
|
12,373 |
6,062 |
$102K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,951 |
2,631 |
$96K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
560 |
466 |
$86K |
| 96376 |
|
2,852 |
1,720 |
$85K |
| 83880 |
|
2,908 |
2,439 |
$75K |
| 80050 |
General health panel |
2,838 |
1,646 |
$74K |
| 36415 |
Collection of venous blood by venipuncture |
48,777 |
13,520 |
$74K |
| 94760 |
|
7,611 |
6,419 |
$73K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,717 |
1,047 |
$73K |
| 97161 |
|
2,329 |
1,486 |
$73K |
| 93017 |
|
573 |
550 |
$64K |
| 83690 |
|
10,188 |
7,906 |
$56K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,159 |
2,594 |
$55K |
| 83735 |
|
10,437 |
7,889 |
$54K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
330 |
276 |
$53K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
7,366 |
6,369 |
$52K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,771 |
1,693 |
$52K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,435 |
1,109 |
$48K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
8,231 |
6,293 |
$47K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
185 |
102 |
$46K |
| 73630 |
|
1,302 |
1,104 |
$44K |
| 87634 |
|
747 |
711 |
$44K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,397 |
506 |
$39K |
| 80306 |
|
3,461 |
2,510 |
$39K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
242 |
192 |
$38K |
| 83605 |
|
4,409 |
3,114 |
$38K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,574 |
2,049 |
$38K |
| 74022 |
|
1,027 |
910 |
$34K |
| J7050 |
Infusion, normal saline solution, 250 cc |
3,287 |
1,663 |
$33K |
| 87040 |
|
3,978 |
1,986 |
$33K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
7,299 |
4,715 |
$32K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
585 |
559 |
$31K |
| 81001 |
|
12,694 |
9,781 |
$30K |
| 72131 |
|
240 |
157 |
$30K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,652 |
3,076 |
$29K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,604 |
1,480 |
$29K |
| 73130 |
|
777 |
692 |
$27K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,953 |
1,762 |
$26K |
| J3490 |
Unclassified drugs |
1,740 |
1,029 |
$26K |
| 73610 |
|
722 |
627 |
$25K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,146 |
1,047 |
$23K |
| 82550 |
|
4,362 |
3,573 |
$23K |
| 73562 |
|
617 |
496 |
$21K |
| J2704 |
Injection, propofol, 10 mg |
2,474 |
2,192 |
$21K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,300 |
2,898 |
$21K |
| 84703 |
|
3,368 |
3,041 |
$21K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,080 |
968 |
$20K |
| 82948 |
|
8,912 |
1,698 |
$20K |
| 73030 |
|
651 |
520 |
$20K |
| 80061 |
Lipid panel |
1,955 |
1,569 |
$20K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
162 |
150 |
$19K |
| 85379 |
|
2,069 |
1,799 |
$18K |
| 87186 |
|
2,161 |
1,733 |
$17K |
| 82150 |
|
3,072 |
2,678 |
$16K |
| 81025 |
|
2,246 |
2,041 |
$16K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,018 |
774 |
$16K |
| 85610 |
|
4,677 |
3,734 |
$14K |
| 86140 |
|
2,986 |
2,150 |
$14K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,275 |
1,045 |
$14K |
| 96367 |
|
1,032 |
492 |
$13K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,912 |
1,097 |
$13K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,036 |
818 |
$13K |
| 87077 |
|
2,122 |
1,420 |
$13K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
53 |
49 |
$12K |
| 97162 |
|
366 |
201 |
$12K |
| 97012 |
|
437 |
153 |
$11K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,188 |
1,038 |
$11K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
403 |
347 |
$11K |
| 87081 |
|
1,773 |
1,563 |
$11K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,736 |
2,037 |
$10K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
200 |
190 |
$10K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
82 |
79 |
$10K |
| 82553 |
|
916 |
766 |
$9K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,171 |
1,921 |
$9K |
| 82803 |
|
572 |
384 |
$9K |
| 84145 |
|
690 |
346 |
$9K |
| 12001 |
|
118 |
108 |
$9K |
| 85730 |
|
1,705 |
1,489 |
$9K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
698 |
568 |
$9K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
179 |
174 |
$9K |
| 90715 |
|
166 |
160 |
$8K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1,718 |
1,562 |
$8K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,226 |
1,091 |
$8K |
| C9113 |
Injection, pantoprazole sodium, per vial |
991 |
629 |
$8K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,213 |
1,901 |
$7K |
| 72110 |
|
255 |
194 |
$7K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
18 |
14 |
$7K |
| 74018 |
|
188 |
168 |
$7K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
283 |
212 |
$7K |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
127 |
112 |
$7K |
| 73110 |
|
197 |
176 |
$7K |
| 87807 |
|
549 |
511 |
$6K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
126 |
122 |
$6K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
291 |
237 |
$5K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
69 |
51 |
$5K |
| 72100 |
|
180 |
136 |
$5K |
| 81003 |
|
2,766 |
2,389 |
$5K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
489 |
432 |
$5K |
| 0012A |
|
269 |
260 |
$5K |
| 97164 |
|
158 |
151 |
$4K |
| 0011A |
|
287 |
275 |
$4K |
| 82607 |
|
373 |
332 |
$4K |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
167 |
144 |
$4K |
| 73221 |
|
14 |
13 |
$3K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
926 |
805 |
$3K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
34 |
30 |
$3K |
| 93225 |
|
26 |
25 |
$3K |
| 73090 |
|
58 |
51 |
$3K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
513 |
414 |
$3K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,641 |
1,416 |
$3K |
| 94060 |
|
25 |
24 |
$2K |
| 93270 |
|
93 |
82 |
$2K |
| 90714 |
|
130 |
113 |
$2K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
12 |
12 |
$2K |
| 0001A |
|
85 |
81 |
$2K |
| 99218 |
|
45 |
16 |
$2K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
392 |
314 |
$2K |
| 94729 |
|
38 |
37 |
$2K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
285 |
242 |
$2K |
| 92523 |
|
12 |
12 |
$2K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
92 |
74 |
$1K |
| 94726 |
|
36 |
26 |
$1K |
| J3480 |
Injection, potassium chloride, per 2 meq |
129 |
69 |
$1K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
91 |
81 |
$1K |
| 12002 |
|
14 |
13 |
$1K |
| 0013A |
|
84 |
79 |
$1K |
| 71101 |
|
38 |
25 |
$1K |
| 87205 |
|
322 |
269 |
$1K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
29 |
27 |
$920.16 |
| J2060 |
Injection, lorazepam, 2 mg |
270 |
191 |
$874.99 |
| 84439 |
|
123 |
120 |
$864.12 |
| 73080 |
|
33 |
24 |
$798.99 |
| 84702 |
|
57 |
44 |
$776.92 |
| 99406 |
|
77 |
65 |
$684.66 |
| 0002A |
|
65 |
65 |
$635.60 |
| 82962 |
|
232 |
188 |
$632.24 |
| 93242 |
|
66 |
64 |
$625.87 |
| 0003A |
|
46 |
46 |
$606.10 |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
50 |
13 |
$445.49 |
| 83550 |
|
49 |
27 |
$421.24 |
| 73502 |
|
13 |
12 |
$420.00 |
| 73564 |
|
15 |
12 |
$417.00 |
| J7510 |
Prednisolone oral, per 5 mg |
39 |
36 |
$387.77 |
| 73590 |
|
16 |
12 |
$387.45 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
15 |
14 |
$323.23 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
394 |
336 |
$288.92 |
| 84100 |
|
75 |
54 |
$269.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
14 |
13 |
$252.25 |
| 85027 |
|
34 |
27 |
$241.57 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
27 |
26 |
$238.12 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
46 |
28 |
$227.32 |
| 0134A |
|
13 |
12 |
$155.80 |
| J0592 |
Injection, buprenorphine hydrochloride, 0.1 mg |
17 |
17 |
$153.85 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
44 |
30 |
$153.45 |
| 85652 |
|
57 |
49 |
$126.28 |
| 83540 |
|
30 |
27 |
$110.85 |
| 87075 |
|
15 |
12 |
$85.23 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
18 |
13 |
$80.71 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
44 |
37 |
$73.46 |
| 85007 |
|
19 |
15 |
$63.10 |
| 81002 |
|
36 |
26 |
$62.64 |
| 82043 |
|
15 |
12 |
$49.17 |
| 86901 |
|
13 |
12 |
$35.88 |
| 86900 |
|
13 |
12 |
$35.88 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
236 |
184 |
$1.50 |
| 3044F |
|
128 |
120 |
$0.01 |
| A9270 |
Non-covered item or service |
65 |
12 |
$0.00 |